Penumbra Inc (PEN) Stock
PEN has an Alpha Score of 43 out of 100 (weak), computed on Aug 29, 2026 from 3 of 4 sub-scores. 1 member of Congress disclosed 1 trade in PEN since 2025: 0 purchases and 1 sale, most recently Lisa McClain (sale, Jul 10, 2025). 8 of the hedge funds AlphaScala tracks reported PEN in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $221.22M. Its trailing P/E ratio is 79.5 and its net margin 10.7% (key statistics as of Oct 21, 2026).
What is PEN's Alpha Score?
How it works →Alpha Score of 43 reflects weak overall profile with moderate momentum, poor value, strong quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.
Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Aug 29, 2026 · 54 days ago; due for a rescore
A rules-based research rating, not a recommendation to buy or sell.
Which members of Congress traded Penumbra Inc (PEN)?
Most recent: Lisa McClain (sale, Jul 10, 2025); records start Jul 10, 2025.
| Politician | Trade date | Type | Amount |
|---|---|---|---|
| Lisa McClain R-MI · House | 2025-07-10 | sale | $1k – $15k |
From STOCK Act periodic transaction reports. House filings as of Oct 20, 2026.
See all PEN political trades →Which hedge funds own PEN?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Millennium Management Israel Englander | 701K | $221.22M | -36% |
| Citadel Ken Griffin | 449K | $141.70M | +121% |
| D.E. Shaw David Shaw | 197K | $62.31M | -2% |
| Marshall Wace | 91K | $28.58M | +150% |
| Renaissance Technologies Jim Simons (founder) | 80K | $25.10M | +3581% |
| Point72 Steve Cohen | 7K | $2.07M | NEW |
| Blackstone | 5K | $1.71M | +6% |
| Bridgewater Associates Ray Dalio | 2K | $498.9K | -84% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →What are PEN's key statistics?
Key statistics as of Oct 21, 2026
How does PEN's valuation compare with the Healthcare sector?
| Metric | PEN | Healthcare median | Companies in median |
|---|---|---|---|
| P/E ratio | 79.5 | 27.0 | 75 |
| Net margin | 10.67% | 9.40% | 92 |
| Return on equity | 11.09% | 11.24% | 99 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Oct 22, 2026). P/E excludes loss-making companies.
PEN price chart
Powered by TradingViewWhat does Penumbra Inc do?
Penumbra Inc. is a prominent player in the healthcare sector, focusing primarily on the development and commercialization of innovative medical devices. Known for its customer-centric approach, the company operates within the specialized field of interventional therapies, particularly in neuro and vascular medical devices. Penumbra’s products are crucial for addressing critical conditions such as stroke and peripheral artery diseases. By pioneering minimally invasive solutions, the company significantly contributes to enhancing patient outcomes and reshaping intervention methods in the medical field. Founded in 2004 and headquartered in Alameda, California, Penumbra plays a vital role in the medical device industry with its commitment to advancing healthcare technologies. Its solutions are not only pivotal in specialized medical procedures but also support the healthcare ecosystem's broader objective of improving care and saving lives, making it a key entity amongst healthcare providers and hospitals worldwide.